Patents Issued in July 4, 2024
  • IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS FOR THE EXPANSION OF NK CELLS IN THE TREATMENT OF SOLID TUMOURS
    Publication number: 20240216473
    Abstract: The present disclosure provides methods of treating cancer by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R? protein-Fc domain fusion and either increasing the number of NK cells at least 20-fold as compared to the number of NK cells prior to said administration or resulting in the accumulation of NK cells in the subject. The present disclosure also provides methods for inducing the proliferation of NK cells by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R? protein-Fc domain fusion and either increasing the number of NK cells at least 20-fold as compared to the number of NK cells prior to said administration or resulting in the accumulation of NK cells in the subject.
    Type: Application
    Filed: February 2, 2024
    Publication date: July 4, 2024
    Inventors: Shomyseh Sanjabi, Vittal Shivva, Alexander Joachim Paul Ungewickell, Rajbharan Yadav
  • ACTIVATABLE INTERFERON POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20240216474
    Abstract: Provided herein are IFN polypeptide prodrugs comprising INF, a half-life extension element, an IFN blocking element and a protease cleavable linker. Also provided herein are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors, host cells for making such polypeptide prodrugs. Also disclosed are methods of using the polypeptide prodrugs in the treatment of diseases, conditions and disorders.
    Type: Application
    Filed: February 13, 2024
    Publication date: July 4, 2024
    Inventors: William WINSTON, Daniel HICKLIN, Jose Andres SALMERON-GARCIA, Cynthia SEIDEL-DUGAN, Heather BRODKIN, Philipp STEINER
  • GLP-1 COMPOSITIONS AND USES THEREOF
    Publication number: 20240216475
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: January 30, 2024
    Publication date: July 4, 2024
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND
    Publication number: 20240216476
    Abstract: There is disclosed a combination oral dosage form pharmaceutical composition comprising a bitter receptor agonist and a gut-signaling compound. i.e., a gut-signaling peptide analog and/or gut-signaling hormone enhancer. And there is disclosed a method for treating obesity, diabetes, metabolic syndrome, glycemic control hyperlipidemia, and effecting weight loss comprising administering an effective amount of a pharmaceutical composition comprising a bitter receptor agonist and a gut-signaling compound, i.e., a gut-signaling peptide analog and/or gut-signaling hormone enhancer, as described above and herein.
    Type: Application
    Filed: April 26, 2022
    Publication date: July 4, 2024
    Applicant: AARDVARK THERAPEUTICS, INC.
    Inventors: Zhenhuan ZHENG, Andreas NIETHAMMER, Anjuli TIMMER, Tien-Li LEE
  • USE OF THERAPEUTIC PLASMA EXCHANGE AND LOW VOLUME PLASMA EXCHANGE FOR THE TREATMENT OF A COGNITIVE IMPAIRMENT
    Publication number: 20240216477
    Abstract: A composition including human albumin at a concentration between 5% (w/v) and 25% (w/v) is for the treatment of a cognitive impairment by conventional therapeutic plasma exchange (TPE) and low-volume plasma exchange (LVPE) in a patient in need thereof. The patient has a Mini Mental State Examination (MMSE) greater or equal to 15.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 4, 2024
    Inventors: Victor GRIFOLS ROURA, Antonio Manuel PAEZ REGADERA, Laura NUÑEZ DOMENECH
  • FIBROIN-DERIVED PROTEIN COMPOSITION
    Publication number: 20240216478
    Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.
    Type: Application
    Filed: February 2, 2024
    Publication date: July 4, 2024
    Applicant: SILK TECHNOLOGIES, LTD.
    Inventors: Brian D. LAWRENCE, David W. INFANGER
  • ENCAPSULATION OF DUAL-ENZYME COMPOSITION FOR PREVENTING, TREATING AND/OR ALLEVIATING VEISALGIA AND SYMPTOMS ASSOCIATED THEREWITH
    Publication number: 20240216479
    Abstract: An encapsulated composition for converting ethanol to acetaldehyde and subsequently converting the acetaldehyde to acetate. The composition includes alcohol dehydrogenase and aldehyde dehydrogenase in a molar ratio of approximately 1:3 to approximately 1:51. The composition is encapsulated by a polysaccharide-whey-casein encapsulant such that the encapsulated composition has a controlled release property in the small intestine. The composition reduces symptoms caused by over-consumption of alcohol.
    Type: Application
    Filed: September 12, 2023
    Publication date: July 4, 2024
    Inventors: Bing Lou WONG, Sek Lun LAW, Joo Ann EWE, Chun Hay KO
  • TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE
    Publication number: 20240216480
    Abstract: This disclosure relates to the application of the enzyme fructosyl-amino acid oxidase (FAOD)—without the addition of proteases—in medical and cosmetical conditions that are characterized by the presence of advanced glycation end products (AGEs). More specifically, this disclosure relates to the treatment of eye diseases in humans or animals. AGEs accumulate in the aging eye causing presbyopia, cataract, dry eyes, age-related macular degeneration, glaucoma and diabetic retinopathy. Hence, the disclosure relates to the application of FAOD in order to deglycate and inactivate the AGEs.
    Type: Application
    Filed: March 7, 2022
    Publication date: July 4, 2024
    Inventors: Joris Delanghe, Elisabeth Van Aken
  • COMPOSITION FOR TREATING OF FACIAL DYSMORPHISM IN MUCOPOLYSACCHARIDOSIS
    Publication number: 20240216481
    Abstract: A composition and a use thereof in treating facial dysmorphism in mucopolysaccharidosis are disclosed.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 4, 2024
    Applicants: GREEN CROSS CORPORATION, Dong Kyu JIN
    Inventor: Dong Kyu JIN
  • SYSTEMS AND METHODS FOR REGULATING ABERRANT GENE EXPRESSIONS
    Publication number: 20240216482
    Abstract: The disclosure provides systems, compositions, methods for regulating aberrant expression of a target gene in cell (e.g., a muscle cell), to treat or ameliorate a disease or a condition in a subject (e.g., muscular dystrophy, such as Facioscapulohumeral Muscular Dystrophy (FSHD)).
    Type: Application
    Filed: December 15, 2023
    Publication date: July 4, 2024
    Inventors: Alexandra Sylvie Collin de l’Hortet, Rosemarie Wenting Tsoa, Abhinav Adhikari, Siddaraju Boregowda, Daniel O. Hart, Thomas Blair Gainous, Giovanni Carosso, Xiao Yang, Timothy Daley, Thao Nguyen Vu Luong, Yanxia Liu, Tengyu KO, Amber Ruth Salzman
  • THERAPEUTIC REGIMEN WITH DNASE
    Publication number: 20240216483
    Abstract: The invention provides methods for induction of pregnancy in a couple in need thereof wherein the male subject in said couple has been diagnosed as sub-fertile, said method comprising administering systemically to said male subject a pharmaceutical composition comprising a human DNase.
    Type: Application
    Filed: May 24, 2022
    Publication date: July 4, 2024
    Applicant: PERI-NESS TECHNOLOGIES LTD
    Inventors: Moshe MIZRAHY, Dmitry GENKIN
  • BROMELAIN PROTEASE, BROMELAIN, JACALIN-LIKE LECTIN, EXTRACT FROM THE STEM AND/OR THE FRUIT OF A PINEAPPLE PLANT, COMBINATION PREPARATION, BROMELAIN PROTEASE INHIBITOR, PROTEIN/PROTEASE MIX, AND GLYCATED BROMELAIN PROTEIN FORMED BY EXOGENOUS NON-ENZYMATIC GLYCATION, FOR USE IN THE TREATMENT OR PROPHYLAXIS OF VIRUS INFECTIONS CAUSED BY CORONAVIRUSES IN A HUMAN OR ANIMAL
    Publication number: 20240216484
    Abstract: The present invention addresses the problem of indicating active-ingredient classes which can treat virus diseases caused by coronaviruses in a human or animal. Said treatment includes the acute treatment of an already existing virus disease and the prophylaxis of same. The present invention relates to a bromelain protease, bromelain, jacalin-like lectin, extract from the stem and/or the fruit of a pineapple plant, combination preparation, bromelain protease inhibitor, protein/protease mix, and glycated bromelain protein formed by exogenous non-enzymatic glycation, for use in the treatment or prophylaxis of virus infections caused by coronaviruses in a human or animal.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 4, 2024
    Applicants: URSAPHARM ARZNEIMITTEL GMBH, HOCHSCHULE KAISERSLAUTERN, HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND
    Inventors: Peter GROSS, Rolf MÜLLER, Frank HOLZER, Peter MEISER, Holger SEELERT
  • METHOD OF TREATING OR REDUCING EFP
    Publication number: 20240216485
    Abstract: The present invention is directed to a method of treating or reducing EFP in a patient comprising administering one or multiple low dose injections of collagenase to an area affected by EFP. The invention encompasses methods wherein the dose of collagenase per injection is between about 50 to about 200 ABC units and/or wherein the concentration of collagenase is between about 50 to about 2000 ABC units/milliliter (ml).
    Type: Application
    Filed: January 17, 2024
    Publication date: July 4, 2024
    Inventor: Susan G. Emeigh Hart
  • INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES
    Publication number: 20240216486
    Abstract: Provided is an invention based on methods to treat or prevent headaches with injectable compositions comprising botulinum toxin that may be administered using an injection paradigm that provides botulinum toxin at one or more locations of neuronal activity associated with EEG detectable brain cortical electrical activity to a subject suffering from such malady. Co-therapeutics therewith are also disclosed.
    Type: Application
    Filed: September 10, 2023
    Publication date: July 4, 2024
    Inventors: Mahan Chehrenama, Stephen Silberstein, Rami Burstein, Peter McAllister, Paul Matthew, Andrew Blumenfeld, Jessica Ailani, David Dodick, Roman Rubio
  • INTRAMUSCULAR COMPOSITIONS OF BOTULINUM NEUROTOXINS
    Publication number: 20240216487
    Abstract: The present disclosure provides fusion proteins combining botulinum neurotoxins (BoNTs) and cell penetration peptides (CPP) which are suitable for intramuscular administration. These fusion proteins have exceptional cellular uptake ability, potent therapeutic efficacy, and considerably increased therapeutic index when compared to the BoNT protein alone or the commercial product BOTOX® onabotulinumtoxinA. Also provided are BONT fusion proteins that are not cleaved to form two-chain polypeptides but yet retaining strong enzymatic activities. Such single-chain active BONT fusion proteins can be prepared from insect cells.
    Type: Application
    Filed: April 26, 2022
    Publication date: July 4, 2024
    Inventors: Jia LIU, Xuan WEI, Lu LI
  • COMPLEX OF BOTULINUM NEUROTOXIN E AND ITS BINDING PROTEIN AS A FORMULATION WITH ENHANCED POTENCY
    Publication number: 20240216488
    Abstract: Methods of making the M or L complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), and methods of using to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.
    Type: Application
    Filed: March 11, 2024
    Publication date: July 4, 2024
    Applicant: Institute of Advanced Sciences, Inc.
    Inventors: Bal Ram Singh, Raj Kumar
  • IMMUNE TOLERANCE INDUCTION AND ERADICATION OF ANTI-DRUG ANTIBODIES (ADA) TO THERAPEUTIC FACTOR VIII
    Publication number: 20240216489
    Abstract: Methods for immune tolerance induction and eradication of anti-drug antibodies to therapeutic Factor VIII are disclosed.
    Type: Application
    Filed: April 20, 2022
    Publication date: July 4, 2024
    Inventor: Valder R. Arruda
  • Autoantigens Engineered to Suppress Autoimmune Response
    Publication number: 20240216490
    Abstract: The present disclosure provides engineered antigen compositions that reduce immune response to the antigen in a subject having an immune response to the antigen. The present disclosure also provides pharmaceutical compositions that include such engineered autoantigens and methods for making such engineered autoantigens. Methods for using such engineered antigens as therapeutics and in research are also disclosed.
    Type: Application
    Filed: July 12, 2023
    Publication date: July 4, 2024
    Inventors: Richard James Glynne, Tigran Aivazian, James Paulson
  • NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS
    Publication number: 20240216491
    Abstract: Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described.
    Type: Application
    Filed: February 5, 2024
    Publication date: July 4, 2024
    Inventors: Tze Chieh SHIAO, Serge MOFFETT, Serge MIGNANI, Rene ROY
  • USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER
    Publication number: 20240216492
    Abstract: The disclosure relates to the use of oncolytic adenoviruses for the treatment of pediatric brain tumors, such as, for example, diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: April 26, 2022
    Publication date: July 4, 2024
    Inventors: Erin MITCHELL, Frank TUFARO, Marta ROLDÁN, Sonia TEJADA-SOLIS, Jaime PÉREZ DE LARRAYA
  • CANCER THERAPY COMPOSITIONS AND USES THEREOF
    Publication number: 20240216493
    Abstract: The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 4, 2024
    Inventors: Steven Gregory Reed, Darrick Albert Carter, Malcolm Scott Duthie, Lars Peter Aksel Berglund, Jesse Hong-Sae Erasmus, Jiho Kim
  • PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE
    Publication number: 20240216494
    Abstract: Provided herein are isolated proteins isolatable from a Klebsiella spp. Also provided are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.
    Type: Application
    Filed: December 6, 2023
    Publication date: July 4, 2024
    Inventors: Douglas T. Burkhardt, Daryll Emery, Darren Straub
  • COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE
    Publication number: 20240216495
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
    Type: Application
    Filed: August 9, 2023
    Publication date: July 4, 2024
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G.K. Donald, Michael James Flint, Nicholas Randolph Everard Kitchin, Justin Keith Moran, Louise Pedneault, Michael W. Pride, Mark Edward Ruppen, Christopher Frederick Webber
  • RECOMBINANT LACTIC ACID BACTERIUM AND METHOD THEREOF FOR SIMULTANEOUS TREATMENT AND/OR PREVENTION OF DUST MITE AND COCKROACH ALLERGIES
    Publication number: 20240216496
    Abstract: A recombinant lactic acid bacterium and a method thereof for simultaneous treatment and/or prevention of dust mite and cockroach allergies. The recombinant lactic acid bacterium has a gene fragment with nucleotide coded as SEQ ID No: 1 to be capable of expressing the D2P2 protein with amino acid sequence of SEQ ID No: 2. Therefore, by administering an effective amount of the recombinant lactic acid bacterium to an individual is capable of effectively causing the individual's body to produce antibodies against dust mite and/or cockroach allergens, thereby achieving an efficacy of preventing and/or treating an allergic disease caused by dust mite and/or cockroach allergens.
    Type: Application
    Filed: June 7, 2023
    Publication date: July 4, 2024
    Inventors: Mey Fann LEE, Yi-Hsing CHEN
  • Ferritin Proteins
    Publication number: 20240216497
    Abstract: Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.
    Type: Application
    Filed: January 12, 2024
    Publication date: July 4, 2024
    Applicant: SANOFI
    Inventors: Gary J. Nabel, Chih-Jen Wei, Kurt Swanson
  • LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE
    Publication number: 20240216498
    Abstract: The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.
    Type: Application
    Filed: November 29, 2023
    Publication date: July 4, 2024
    Applicant: Takeda Vaccines, Inc.
    Inventors: Joseph David Santangelo, Jill A. Livengood, Yock Ann Lee, Weiwen Luo
  • PROTEIN-BASED NANOPARTICLE VACCINE FOR METAPNEUMOVIRUS
    Publication number: 20240216499
    Abstract: Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.
    Type: Application
    Filed: September 6, 2023
    Publication date: July 4, 2024
    Inventors: Andrew Lawrence Feldhaus, Douglas Andrew Holtzman, Clancey Buchanan Wolf
  • RESPIRATORY VIRUS COMBINATION VACCINES
    Publication number: 20240216500
    Abstract: The disclosure provides combination mRNA vaccines for respiratory viruses, as well as methods of using the vaccines.
    Type: Application
    Filed: April 12, 2022
    Publication date: July 4, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Raffael Nachbagauer, Carole Henry, Guillaume Stewart-Jones, Elisabeth Narayanan, Hamilton Bennett, Andrea Carfi
  • NEOANTIGEN ADJUVANT AND MAINTENANCE THERAPY
    Publication number: 20240216501
    Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccination strategy.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 4, 2024
    Inventors: Raphael Rousseau, Andrew Ferguson, Karin Jooss
  • UNIVERSAL VACCINE PLATFORM
    Publication number: 20240216502
    Abstract: The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.
    Type: Application
    Filed: November 8, 2023
    Publication date: July 4, 2024
    Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Hugh MASON, Andrew DIAMOS, Mary PARDHE, Brandon FAVRE
  • METHODS OF TREATING ALLERGIES
    Publication number: 20240216503
    Abstract: Provided are methods of treating or preventing allergies comprising administering mixed allergen compositions to subjects.
    Type: Application
    Filed: February 23, 2022
    Publication date: July 4, 2024
    Inventors: Ashley Dombkowski, Dana McClintock, Preeti Lal, Amy Sullivan, Varghese Abraham, Nusrat Rabbee, James Kirchner, Amelia Milani
  • METHOD FOR PREVENTING OR TREATING OF HEMATHROSIS
    Publication number: 20240216504
    Abstract: A pharmaceutical composition capable of exhibiting excellent efficacy against hemathrosis by including an anti-TFPI antibody and hyaluronic acid. A use of the pharmaceutical composition is also disclosed. A method for preventing or treating hemathrosis in a subject in need thereof, includes administering to the subject an effective amount of a pharmaceutical composition comprising an anti-TFPI antibody and hyaluronic acid.
    Type: Application
    Filed: December 30, 2022
    Publication date: July 4, 2024
    Applicants: GREEN CROSS CORPORATION
    Inventor: Dong Kyu JIN
  • INDUCIBLE CYTOKINE PRODRUG AND PD-1/PD-L1 COMBINATION THERAPY
    Publication number: 20240216505
    Abstract: This disclosure relates to methods and compositions for treating cancer including lymphoma using an inducible cytokine prodrug, and to a combination therapy comprising an inducible cytokine prodrug in combination with anti-PD-1 and anti-PD-L1 antibodies.
    Type: Application
    Filed: February 13, 2024
    Publication date: July 4, 2024
    Inventors: William WINSTON, Daniel HICKLIN, Jose Andres SALMERON-GARCIA, Cynthia SEIDEL-DUGAN, Heather BRODKIN, Philipp STEINER
  • ANTIBODY COMPOSITION
    Publication number: 20240216506
    Abstract: The invention relates to a stable liquid aqueous pharmaceutical formulation comprising an anti-interleukin 36 receptor (IL-36R) antibody or antigen binding antibody fragment; a buffer; a stabilizer; and a surfactant, and methods of treating a subject with the pharmaceutical formulation.
    Type: Application
    Filed: May 12, 2022
    Publication date: July 4, 2024
    Inventors: Alex Praseuth, Kevin Zen, Laurence Altobell, III, Margaret H. Marino
  • SARS-COV-2-SPECIFIC T CELLS AND METHODS OF TREATMENT USING THEM
    Publication number: 20240216507
    Abstract: The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 4, 2024
    Applicant: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Catherine BOLLARD, Michael KELLER, Chris LAZARSKI, Allistair ABRAHAM, Patrick HANLEY, Conrad Russell Y. CRUZ
  • ENGINEERED T CELLS CONDITIONALLY EXPRESSING A RECOMBINANT RECEPTOR, RELATED POLYNUCLEOTIDES AND METHODS
    Publication number: 20240216508
    Abstract: Provided are engineered T cells that contain a modified T cell stimulation-associated locus encoding a recombinant receptor or a portion thereof. In some aspects, the nucleic acid sequence encoding the recombinant receptor or a portion thereof is operably linked to an endogenous transcriptional regulatory element of the T cell stimulation-associated locus, in some cases, engineered by targeted integration. In some aspects, the engineered cells conditionally express the recombinant receptor, such as upon stimulation or activation signal in the T cell. Also disclosed are cell compositions, nucleic acids for engineering cells, and methods and articles of manufacture for producing the engineered cells. In some embodiments, the engineered cells can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.
    Type: Application
    Filed: June 25, 2021
    Publication date: July 4, 2024
    Applicant: Juno Therapeutics GmbH
    Inventors: Mateusz Pawel POLTORAK, Christian STEMBERGER, Lothar GERMEROTH
  • CHIMERIC POLYPEPTIDES, NUCLEIC ACID MOLECULES, CELLS, AND RELATED METHODS
    Publication number: 20240216509
    Abstract: Some embodiments of the invention include chimeric polypeptides. Other embodiments of the invention include chimeric nucleic acid molecules encoding a chimeric polypeptide. Other embodiments of the invention include vectors comprising a chimeric nucleic acid molecule. Still other embodiments of the invention include cells comprising a chimeric nucleic acid molecule, a chimeric polypeptide, or both. Yet other embodiments of the invention include methods of making cells. Some embodiments include methods of treating disease. Additional embodiments of the invention are also discussed herein.
    Type: Application
    Filed: May 6, 2019
    Publication date: July 4, 2024
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Stephen WAGGONER, Hermine BRUNNER, Seth REIGHARD
  • CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN
    Publication number: 20240216510
    Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to Sialyl Tn carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.
    Type: Application
    Filed: April 13, 2022
    Publication date: July 4, 2024
    Inventors: Vered PADLER-KARAVANI, Ron AMON, Lihi NINIOMANY, Moran RAWET SLOBODKIN, Anat GLOBERSON LEVIN, Tova WAKS, Zelig ESHHAR
  • THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS
    Publication number: 20240216511
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 4, 2024
    Applicant: Fennec Pharmaceuticals, Inc.
    Inventor: Alexander Smith
  • INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION
    Publication number: 20240216512
    Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.
    Type: Application
    Filed: November 2, 2023
    Publication date: July 4, 2024
    Inventors: Andres Garcia, Benjamin Maynor, Janet Tully, Benjamin Robinson Yerxa, Tomas Navratil, Sanjib Kumar Das
  • FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE
    Publication number: 20240216513
    Abstract: Described herein are fatty acid-bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: March 10, 2022
    Publication date: July 4, 2024
    Inventors: Claire Adcock, Valerie Broennimann, Jiashun Cheng, Rohit Kumar Duvadie, Tanzina Fazal, Jinhai Gao, Fengfeng Guo, Robert Martin Grotzfeld, Christina Hebach, Gregory John Hollingworth, Darryl Brynley Jones, Alexei Karpov, Jialiang Li, Julien Lorber, Chester A. Metcalf, III, Walter Michael, Mark Gabriel Palermo, Scott Vaughan Plummer, James Harold Roache, Martin Sendzik, Ranny Mathew Thomas, Aimee Richardson Usera, Anna Vulpetti, Frederic Zecri, Liang Zhao, Thomas Zoller
  • NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE
    Publication number: 20240216514
    Abstract: Novel compounds and compositions including the same and methods of manufacturing and using the same, particularly for use as an anticancer/antitumor drug and/or for oncological indications. Novel compounds comprising or formed as conjugates of cisplatin, oxaliplatin, or other platinum moiety, particularly platinum(IV) moiety, and/with one or more moiety of 4-(phenylthio)butanoic acid (PTBA) or derivative of PTBA, and to compositions comprising the same, and to methods of manufacturing and using the same, particularly for use as an anticancer/antitumor drug and/or for oncological indications. Novel anticancer agents comprising a chemical conjugation of a platinum moiety and the therapeutically active ligand 4-(phenylthio)butyrate or a derivative thereof, as a drug or prodrug for cancer treatment.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 4, 2024
    Inventors: Noriyuki KASAHARA, Michael Joseph Bishop, James Plante
  • COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
    Publication number: 20240216515
    Abstract: Described herein are compositions, kits, and methods for potent delivery to a ceil of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. Tire lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 4, 2024
    Inventors: Michael Torres, Daniel J. Siegwart, Jackson Eby, Rumpa Bhattacherjee, Brandon Wustman, Vladimir Kharitonov, Qiang Cheng, Tuo Wei
  • GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF
    Publication number: 20240216516
    Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.
    Type: Application
    Filed: November 30, 2023
    Publication date: July 4, 2024
    Inventors: Ji LIU, Robert LUO, Pin HUANG, Jie SU, Yan FENG, Ke LIU, Jie FAN, Wei HE, Yimin QIAN
  • PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LUNG CANCER
    Publication number: 20240216517
    Abstract: A protein has the molecule capable of binding to the immune checkpoint molecule fused to an outer surface thereof and thus may be used as an immune checkpoint inhibitor. A method for treating a lung cancer includes administering to a subject in need thereof a composition comprising a ferritin protein in which a molecule capable of binding to an immune checkpoint molecule is fused to an outer surface of the protein.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 4, 2024
    Inventors: Jee Won LEE, Bo Ram LEE
  • EXTENDED-RELEASE IMMUNE CELL ENGAGING PROTEINS AND METHODS OF TREATMENT
    Publication number: 20240216518
    Abstract: Provided herein are descriptions of extended-release immune cell binding protein comprising a masking peptide and cleavable linker, and the methods of using thereof. Also described is a pharmaceutical composition comprising a protein with a masking peptide and a cleavable linker, and the method of using thereof.
    Type: Application
    Filed: November 30, 2023
    Publication date: July 4, 2024
    Inventors: Holger WESCHE, Shuoyen Jack LIN, Kathryn KWANT, Bryan D. LEMON, Richard J. AUSTIN
  • SMALL HYDROPHOBIC PROTEIN DRUG CONJUGATES AND USES THEREOF
    Publication number: 20240216519
    Abstract: The present disclosure provides peptide conjugated drugs based on MuV SH Protein, their use as therapeutic agents and their use to provide delivery to and/or transfer across a membrane of the drug. The present disclosure provides use of the peptide conjugated drug for delivery of the drug to and/or across a membrane harbouring G protein-coupled receptor 125 (GPR125), such as the choroid plexus.
    Type: Application
    Filed: April 25, 2022
    Publication date: July 4, 2024
    Inventors: Mette Marie ROSENKILDE, Katja SPIESS, Lola Julie Torz PEDERSEN, Maja Lind Nybo HENNINGSEN, Katrine QVORTRUP
  • PEPTIDE-SMALL INTERFERING RNA-HYALURONIC ACID NANOPARTICLES AND METHODS OF USE THEREOF
    Publication number: 20240216520
    Abstract: The present disclosure provides nanoparticle compositions and their use in the treatment of viral infections.
    Type: Application
    Filed: April 6, 2022
    Publication date: July 4, 2024
    Inventors: Samuel WICKLINE, Hua PAN
  • METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES
    Publication number: 20240216521
    Abstract: The present invention provides methods of preparing a cell-binding agent-cytotoxic agent conjugate comprising a cell-binding agent (CysCBA) having one or more unpaired cysteine residues covalently linked to a cytotoxic agent. Also provided are conjugates prepared by the methods described herein and pharmaceutical composition and methods of use thereof.
    Type: Application
    Filed: October 23, 2023
    Publication date: July 4, 2024
    Inventors: Scott A. Hilderbrand, Daniel F. Milano
  • MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
    Publication number: 20240216522
    Abstract: The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target FXN RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload increases expression or activity of a FXN allele comprising a disease-associated-repeat.
    Type: Application
    Filed: June 17, 2022
    Publication date: July 4, 2024
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Cody A. Desjardins, Oxana Beskrovnaya, Timothy Weeden, Mohammed T. Qatanani, Brendan Quinn, John Najim, Victor Kotelianski, Duncan Brown